Sickle Cell Anemia: Understanding Red Blood Cell Circulation Issues

Pathophysiology

Sickle cell disease (SCD) — autosomal recessive mutation in HBB (β-globin): Glu6Val → hemoglobin S (HbS). Deoxygenated HbS polymerizes into rigid fibers, distorting RBCs into sickle shape.

Vaso-Occlusive Crisis (VOC)

Sickled RBCs:

  • Increase blood viscosity
  • Adhere to activated endothelium (VCAM-1, P-selectin)
  • Occlude microvasculature → ischemia-reperfusion injury → severe pain
  • Cause endothelial dysfunction, inflammation, coagulation activation

Major Clinical Manifestations

  • Acute pain crises (bone, chest, abdomen)
  • Acute chest syndrome (infarction + infection + fat embolism) — leading cause of death
  • Stroke (overt & silent; TCD screening in children)
  • Splenic infarction → functional asplenia → encapsulated organism sepsis
  • Chronic hemolytic anemia (reticulocytosis, jaundice, gallstones)
  • Organ damage: Nephropathy (proteinuria, ESRD), retinopathy, avascular necrosis (hip/shoulder), priapism, pulmonary hypertension.

Disease-Modifying Therapies

  • Hydroxyurea: ↑ HbF, ↓ WBC, ↓ adhesion — reduces VOC, ACS, transfusion need.
  • Voxelotor: HbS polymerization inhibitor — ↑ Hb, ↓ hemolysis.
  • Crizanlizumab: Anti-P-selectin — ↓ VOC frequency.
  • L-glutamine: Redox modulation — ↓ VOC.
  • Curative: Allogeneic HSCT (matched sibling best), gene therapy (lentiviral βA-T87Q-globin, CRISPR editing) — emerging.

Preventive Care

  • Penicillin prophylaxis (children <5 yrs)
  • Vaccines: PCV20, PPSV23, MenACWY, Hib, annual flu, COVID
  • Folic acid 1 mg daily
  • TCD screening ages 2–16
  • Comprehensive multidisciplinary clinic

Blood Disorders - Related Articles